Log In
BCIQ
Print this Print this
 

MCLA-128

  Manage Alerts
Collapse Summary General Information
Company Merus N.V.
DescriptionAntibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced human common light chain bispecific IgG1 antibody targeting HER2 and HER3
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) ; Erb-b2 receptor tyrosine kinase 3 (ERBB3) (HER3) (EGFR3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/04/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today